Evidence map›Paper›PMID 36993404›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.

Thandeka Moyo-Gwete, Simone I Richardson, Roanne Keeton, Tandile Hermanus, Holly Spencer, Nelia P Manamela, Frances Ayres, Zanele Makhado, Thopisang Motlou, Marius B Tincho and 15 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 5 institutions in 1 country.

Thandeka Moyo-GweteNational Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
Simone I RichardsonNational Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
Roanne KeetonInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa.
Tandile HermanusNational Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
Holly SpencerNational Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
Nelia P ManamelaNational Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
Frances AyresNational Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
Zanele MakhadoNational Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
Thopisang MotlouNational Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
Marius B TinchoInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa.
Ntombi BenedeInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa.
Amkele NgomtiInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa.
Richard BagumaInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa.
Masego V ChaukeInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa.
Mathilda MennenDepartment of Medicine, University of Cape Town and Groote Schuur Hospital; Observatory, South Africa.
Marguerite AdriaanseDepartment of Medicine, University of Cape Town and Groote Schuur Hospital; Observatory, South Africa.
Sango SkelemDepartment of Medicine, University of Cape Town and Groote Schuur Hospital; Observatory, South Africa.
Ameena GogaSouth African Medical Research Council, Cape Town, South Africa.
Nigel GarrettCentre for the AIDS Programme of Research in South Africa, Durban, South Africa.
Linda-Gail BekkerInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa.
Glenda GraySouth African Medical Research Council, Cape Town, South Africa.
Ntobeko A B NtusiInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa.
Catherine RiouInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa.
Wendy A BurgersInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa.
Penny L MooreNational Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
National Health Laboratory Service · ZAUniversity of Cape Town · ZASouth African Medical Research Council · ZACentre for the AIDS Programme of Research in South Africa · ZADesmond Tutu HIV Foundation · ZA

Funding

Contribution of the CD153/CD30 axis to Mycobacterium tuberculosis control in humansR21AI148027 · NIAID · UNIVERSITY OF CAPE TOWN · PI RIOU, CATHERINE · 2019 to 2020
$291k
NIAID NIH HHS R21 AI148027Wellcome Trust
6 · The paper itself

Abstract

The impact of previous SARS-CoV-2 infection on the durability of Ad26.COV2.S vaccine-elicited responses, and the effect of homologous boosting has not been well explored. We followed a cohort of healthcare workers for 6 months after receiving the Ad26.COV2.S vaccine and a further one month after they received an Ad26.COV2.S booster dose. We assessed longitudinal spike-specific antibody and T cell responses in individuals who had never had SARS-CoV-2 infection, compared to those who were infected with either the D614G or Beta variants prior to vaccination. Antibody and T cell responses elicited by the primary dose were durable against several variants of concern over the 6 month follow-up period, regardless of infection history. However, at 6 months after first vaccination, antibody binding, neutralization and ADCC were as much as 33-fold higher in individuals with hybrid immunity compared to those with no prior infection. Antibody cross-reactivity profiles of the previously infected groups were similar at 6 months, unlike at earlier time points suggesting that the effect of immune imprinting diminishes by 6 months. Importantly, an Ad26.COV2.S booster dose increased the magnitude of the antibody response in individuals with no prior infection to similar levels as those with previous infection. The magnitude of spike T cell responses and proportion of T cell responders remained stable after homologous boosting, concomitant with a significant increase in long-lived early differentiated CD4 memory T cells. Thus, these data highlight that multiple antigen exposures, whether through infection and vaccination or vaccination alone, result in similar boosts after Ad26.COV2.S vaccination.

Indexed as

Ad26.COV2.S vaccineADCCantibodieshybrid immunitymemory differentiationneutralizationSARS-CoV-2T cells

Identifiers

PMID36993404
PMCPMC10055608
OpenAlexW4324316382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.